2026/05/21 by Barkha J. Yadav-Samudrala, Brooke E. Chapple, S A Thompson +4 · 1 voice
Medicine · Pharmacology, Toxicology and Pharmaceutics · Neuroscience · #Cannabis and Cannabinoid Research #Forensic Toxicology and Drug Analysis #Neuroscience and Neuropharmacology Research
paper · doi:10.1177/25785125261450903
openalex publication_date 2026/05/21 · openalex created_date 2026/05/23 · openalex updated_date 2026/07/26
Background: Cannabinoid type 1 receptor (CB 1 R) regulates glutamate release and plays a key role in neuroprotection and neuroinflammation. Since CB 1 R is implicated in HIV-associated neurocognitive disorders (HAND), it is important to determine how its expression changes with the neurotoxic human immunodeficiency virus type-1 (HIV-1) transactivator of transcription (Tat) protein. This study examined CB 1 R dynamics in an inducible HIV-1 Tat transgenic mouse model. Methods: Tat expression was induced in Tat(+) mice using doxycycline (DOX). Longitudinal positron emission tomography (PET) with the CB 1 R-selective radiotracer [ 11 C]-OMAR was performed at baseline, 2 weeks, and 3 months post-induction in Tat(–) and Tat(+) groups to track CB 1 R alterations across brain regions. Western blot analyses were conducted postmortem in the prefrontal cortex, striatum, hippocampus, cortex, cerebellum, and brainstem. Results: In a longitudinal PET imaging study, we observed a significant upregulation of CB 1 R expression in the cortex and cerebellum after 2 weeks of DOX treatment in both Tat(–) and Tat(+) mice; however, this increase was not maintained at the 3-month timepoint. Western blot analysis revealed region-specific changes in CB 1 R levels for both genotypes with upregulation observed at 2 weeks post DOX treatment. Notably, a significant interaction between genotype × DOX in the hippocampus, cerebellum, and brainstem exhibited significant CB 1 R alteration by Tat expression, suggesting region-dependent regulatory mechanisms. Conclusion: DOX treatment and Tat expression appear to affect CB 1 R levels in a region-specific manner, underscoring the complexity of HAND. The differences between PET imaging and Western blot results suggest that [ 11 C]-OMAR may lack the affinity and sensitivity to detect subtle CB 1 R changes at the 3-month timepoint. The low resolution of PET imaging may be another factor contributing to the detection limit. Lastly, these findings emphasize the importance of using multiple methodologies to capture nuanced molecular alterations in neuroinflammatory conditions.